High-dose medroxyprogesterone acetate in patients with renal adenocarcinoma and measurable lung metastases: a phase Ii study
Kjaer, M.; Frederiksen, P.L.
Cancer Treatment Reports 70(3): 431-432
1986
ISSN/ISBN: 0361-5960 PMID: 2937534 Document Number: 275029
Document emailed within 1 workday
Related Documents
Sturm, G.; Antal, E.; Schmidt Rhode, P.; Bauer, T.; Schulz K D. 1986: Medroxyprogesterone acetate and immunoreactive medroxyprogesterone acetate metabolites measured by two different selective radioimmunoassay antibodies in medroxyprogesterone acetate treated breast cancer patients Anticancer Research 6(3 Part A): 362Pannuti, F.; Camaggi, C.M.; Strocchi, E.; Giovannini, M.; Di Marco, A.R.; Costanti, B. 1982: Medroxyprogesterone acetate (MAP) relative bioavailability after single high-dose administration in cancer patients Cancer Treatment Reports 66(12): 2043-2049
Wils, J.A. 1988: Myeloprotective effect of high dose medroxyprogesterone acetate (MPA) Chemioterapia: International Journal of the Mediterranean Society of ChemoTherapy 7(1): 60-62
Telimaa, S.; Kauppila, A.; Rönnberg, L.; Suikkari, A.M.; Seppälä, M. 1989: Elevated serum levels of endometrial secretory protein PP14 in patients with advanced endometriosis. Suppression by treatment with danazol and high-dose medroxyprogesterone acetate American Journal of Obstetrics and Gynecology 161(4): 866-871
Frick, J.; Bartsch, G.; Weiske, W.H. 1977: The effect of monthly depot medroxyprogesterone acetate and testosterone on human spermatogenesis. II. High initial dose Contraception 15(6): 669-677
Sasagawa, I.; Satomi, S.; Katayama, T. 1989: Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma Gan no Rinsho. Japan Journal of Cancer Clinics 35(6): 767-771
Cohen, C.J.; Deppe, G.; Bruckner, H.W. 1977: Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study Obstetrics and Gynecology 50(4): 415-417
Nomura, Y.; Tashiro, H.; Hisamatsu, K.; Toi, M. 1988: Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors Gan to Kagaku Ryoho. Cancer and ChemoTherapy 15(3): 513-518
Ardizzoni, A.; Canobbio, L.; Pronzato, P.; Rubagotti, A.; De Palma, M.; Baracco, F.; Serrano, J.; Serrano, S.; Faravelli, B.; Nosenzo, M. 1986: Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung Cancer Treatment Reports 70(7): 891-892
Starker, W.; Fricke, H.J. 1979: Glucose assimilation under high-dose norethisterone-acetate therapy in adenocarcinoma of the corpus uteri Zentralblatt für Gynakologie 101(7): 473-477
Chandeying, V.; Sangthawan, M. 2007: Efficacy comparison of Pueraria mirifica (PM) against conjugated equine estrogen (CEE) with/without medroxyprogesterone acetate (MPA) in the treatment of climacteric symptoms in perimenopausal women: phase III study Journal of the Medical Association of Thailand 90(9): 1720-1726
Zia, Y.; Tang, J.H.; Chinula, L.; Tegha, G.; Stanczyk, F.Z.; Kourtis, A.P. 2019: Medroxyprogesterone acetate concentrations among HIV-infected depot-medroxyprogesterone acetate users receiving antiretroviral therapy in Lilongwe, Malawi Contraception 100(5): 402-405
Miyawaki, S.; Mizoguchi, H.; Tomonaga, M.; Kanamaru, A.; Tsukagoshi, S.; Nakamura, T.; Ohashi, Y.; Yoshida, S.; Ohno, R. 1998: A phase Ii study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(14): 2229-2242
Iwata, T.; Ando, K.; Mishima, H. 2019: A Case of an Elderly Patient with Multiple Lung Metastases of Postoperative Pancreatic Cancer in Whom Lung Metastases Were Controlled by Biweekly Dose-Down Administration of Gemcitabine Gan to Kagaku Ryoho. Cancer and ChemoTherapy 46(9): 1453-1455
Bruckner, H.W.; Deppe, G. 1977: Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate Obstetrics and Gynecology 50(1 Suppl): 10s-12s
Aabo, K.; Mortensen, S.A.; Skovsgaard, T.; Gymoese, E. 1983: Intermittent high-dose aclarubicin in patients with advanced cancer: a phase I study with special reference to cardiac toxicity Cancer Treatment Reports 67(3): 281-282
Africander, D.J.; Storbeck, K.-H.; Hapgood, J.P. 2014: A comparative study of the androgenic properties of progesterone and the progestins, medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) Journal of Steroid Biochemistry and Molecular Biology 143: 404-415
Piver, M.S.; Barlow, J.J.; Lurain, J.R.; Blumenson, L.E. 1980: Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma Cancer 45(2): 268-272
Chevallier, B. 1990: Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. the Granisetron Study Group European Journal of Cancer 26(Suppl 1): S33-S36
Vereide, A.B.; Kaino, T.; Sager, G.; Ørbo, A. 2005: Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone Gynecologic Oncology 97(3): 740-750